#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure Endpoints NewsMonoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months Medical XpressA Novartis drug cut inflammation. Can it improve heart outcomes? STATPacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial HCPLiveNovartis drug reduced inflammation markers in Phase II study UA.NEWS
#ESC26: Novartis pushes ahead with its IL-6 inhibitor despite Novo’s failure Endpoints NewsMonoclonal antibody targeting interleukin-6 achieves sustained reductions in inflammation biomarkers through six months Medical XpressA Novartis drug cut inflammation. Can it improve heart outcomes? STATPacibekitug Sustains Inflammatory Biomarker Reduction in CKD in TRANQUILITY Trial HCPLiveNovartis drug reduced inflammation markers in Phase II study UA.NEWS
